Information Provided By:
Fly News Breaks for May 13, 2019
BHC, MRK, BDX, KBH, RDS.B, RDS.A
May 13, 2019 | 10:20 EDT
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Royal Dutch Shell (RDS.A, RDS.B) upgraded to Buy from Hold at Deutsche Bank and HSBC. 2. KB Home (KBH) upgraded to Overweight from Equal Weight at Barclays with analyst Matthew Bouley saying his firm's spring agent survey confirmed that housing fundamentals have improved and stabilized. 3. Becton Dickinson (BDX) upgraded to Overweight from Equal Weight at Barclays with analyst Kristen Stewart saying the pullback in the shares since the FDA update on drug-coated balloons on March 15, coupled with the resetting of expectations following the company's Q2 results, provides an opportunity for investors. 4. Merck (MRK) upgraded to Overweight from Neutral at Atlantic Equities. 5. Bausch Health (BHC) upgraded to Neutral from Underweight at JPMorgan with analyst Chris Schott saying while a number of challenges remain in the story given the company's high leverage and controversial Xifaxan loss of exclusivity, its EBITDA is "clearly stabilizing and should begin to grow from here." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
News For B;KBH;BDX;MRK;BHC From the Last 2 Days
KBH
Mar 28, 2024 | 09:33 EDT
Keefe Bruyette raised the firm's price target on KB Home to $74 from $67 and keeps a Market Perform rating on the shares. The analyst increased estimates modestly post the company's Q1 results. While KB looks relatively attractive at 1.2-times forward book value, near mid-cap peers, Keefe has a preference for larger cap builders, the analyst tells investors in a research note.
MRK
Mar 28, 2024 | 06:48 EDT
Merck announced that the European Commission has approved Keytruda, Merck's anti-PD-1 therapy, in combination with platinum-containing chemotherapy as neoadjuvant treatment, then continued as monotherapy as adjuvant treatment, for resectable non-small cell lung cancer at high risk of recurrence in adults.
MRK
Mar 27, 2024 | 16:24 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
MRK
Mar 27, 2024 | 12:00 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.  1... To see the rest of the story go to thefly.com. See Story Here
MRK
Mar 27, 2024 | 08:55 EDT
Check out this morning's top movers from around Wall Street, compiled by The Fly.  HIGHER - Robinhood (HOOD)... To see the rest of the story go to thefly.com. See Story Here
MRK
Mar 27, 2024 | 07:19 EDT
BofA notes that Merck shares have been volatile as investors have contemplated various scenarios regarding the approval of sotatercept and its language, including "a lot of investor angst" given the risk for the FDA to issue either black box warnings, REMS, and/or monitoring requirement. However, sotatercept's approval in PAH with the brand name Winrevair "comes with a squeaky-clean label," without WHO functional class restriction or a need to be on background therapy, no black box and no REMS, which represents "the most bullish scenario," the analyst tells investors. The firm, which anticipates Merck shares to react favorably, maintains a Buy rating and $135 price target and sees upside to sotatercept's commercial outlook.
MRK
Mar 27, 2024 | 06:12 EDT
Wells Fargo raised the firm's price target on Merck to $135 from $130 and keeps an Equal Weight rating on the shares. The firm notes WINREVAIR, or sotatercept, was approved with simple monitoring on the label, removing an overhang on the stock. $242k annual pricing is competitive and could enable the drug to move into earlier lines, and Wells now models $7B peak sales opportunity.
MRK
Mar 26, 2024 | 18:23 EDT
Merck announced that the U.S. FDA has approved sotatercept-csrk for the treatment of adults with pulmonary arterial hypertension to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening events. WINREVAIR was previously granted Breakthrough Therapy Designation by the FDA. WINREVAIR is the first FDA-approved activin signaling inhibitor therapy for PAH, representing a new class of therapy that works by improving the balance between pro- and anti-proliferative signaling to regulate vascular cell proliferation underlying PAH.